 Connection
Carlo Marchetti to Myocardium
This is a "connection" page, showing publications Carlo Marchetti has written about Myocardium.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.228 |
|
|
|
-
Valle Raleigh J, Mauro AG, Devarakonda T, Marchetti C, He J, Kim E, Filippone S, Das A, Toldo S, Abbate A, Salloum FN. Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism. Cardiovasc Res. 2017 May 01; 113(6):609-619.
Score: 0.102
-
Mauro AG, Mezzaroma E, Marchetti C, Narayan P, Del Buono MG, Capuano M, Prestamburgo A, Catapano S, Salloum FN, Abbate A, Toldo S. A Preclinical Translational Study of the Cardioprotective Effects of Plasma-Derived Alpha-1 Anti-trypsin in Acute Myocardial Infarction. J Cardiovasc Pharmacol. 2017 May; 69(5):273-278.
Score: 0.102
-
Toldo S, Mauro AG, Marchetti C, Rose SW, Mezzaroma E, Van Tassell BW, Kim S, Dinarello CA, Abbate A. Recombinant Human Alpha-1 Antitrypsin-Fc Fusion Protein Reduces Mouse Myocardial Inflammatory Injury After Ischemia-Reperfusion Independent of Elastase Inhibition. J Cardiovasc Pharmacol. 2016 Jul; 68(1):27-32.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|